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Introduction {#sec005}
============

*Escherichia coli* is a common commensal organism in the intestinal tracts of humans and animals; it causes a wide range of diseases. Resistance against various antimicrobials, including the cephalosporins, fluoroquinolones, and even the carbapenems, is increasing worldwide \[[@pone.0202276.ref001]\]. The genetic background of such resistance has been extensively studied and varies according to geographic location and time. The *E*. *coli* sequence type (ST) 131 C2/H30Rx clade with the *bla*~CTX-M-15~ gene is largely responsible for the global dissemination of extended-spectrum beta-lactamase-producing *E*. *coli* (ESBL-EC) \[[@pone.0202276.ref002]\]. In Japan, Matsumura et al. evaluated cases of bacteremia due to ESBL-EC between 2005 and 2010 and found the *bla*~CTX-M-14~ gene to be the most common, followed by *bla*~CTX-M-15~ and *bla*~CTX-M-2~ \[[@pone.0202276.ref003]\]. They recently reported on the global emergence and increased prevalence of the *E*. *coli* ST131 clade with the *bla*~CTX-M-27~ gene, named the C1-M27 clade \[[@pone.0202276.ref004]\]. Class A carbapenemases such as *Klebsiella pneumoniae* carbapenemase (KPC), and class B metallo-beta-lactamases such as the New Delhi Metallo-beta-lactamase (NDM), are a problem worldwide; however, these are rarely found in Japan where other types of metallo-beta-lactamases, such as IMP-6, are dominant \[[@pone.0202276.ref005], [@pone.0202276.ref006]\]. Although the incidence is low, Yamamoto et al. recently reported that 14.9% of long-term hospitalized patients harbored carbapenem-resistant Enterobacteriaceae, 95.7% of which produced IMP-6 \[[@pone.0202276.ref007]--[@pone.0202276.ref009]\]. The clinical impact of IMP-6-producing organisms has not yet been reported.

In this study, we aimed to identify the prevalence and genes associated with ESBL-EC and carbapenemase-producing *E*. *coli*, as well as to identify the risk factors and outcomes of patients with bacteremia caused by these organisms.

Materials and methods {#sec006}
=====================

Study setting and study design {#sec007}
------------------------------

This study was conducted at Nara Medical University, a tertiary care hospital with 927 beds in Nara prefecture, located in central Japan. All patients aged 18 years or older with at least one positive blood culture for *E*. *coli* between January 1, 2008, and May 31, 2013, were identified via the clinical microbiology laboratory's computerized database. A case-control study design was used to determine risk factors for the ESBL-EC bacteremia group. The case group comprised patients with ESBL-EC bacteremia and the control group comprised patients with non-ESBL-EC bacteremia. Only the first episode of bacteremia was included for each patient. Ethical approval was obtained from the Institutional Review Board of Nara Medical University (No. 802).

Microbiological analysis {#sec008}
------------------------

The clinical microbiology laboratory used the BacT/Alert 3D blood culture system (Sysmex bioMérieux, Tokyo, Japan) and identification of bacterial isolates was performed using the VITEK^®^ 2 system (Sysmex bioMérieux, Tokyo, Japan). The minimum inhibitory concentration of various antimicrobial agents was determined using the agar dilution method and was interpreted according to the Clinical and Laboratory Standards Institute's (CLSI) guidelines \[[@pone.0202276.ref010]\]. Isolates were reported as being susceptible to flomoxef at a minimum inhibitory concentration of ≤ 8 μg/mL, in reference to the CLSI breakpoint for moxalactam (≤ 8 μg/mL). Screening for ESBL production was performed using the VITEK^®^ 2 Advanced Expert System according to the manufacturer instructions; ESBL production was confirmed using the combined disk test according to CLSI guidelines \[[@pone.0202276.ref010]\]. Bacterial DNA was isolated using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany). Polymerase chain reaction analyses for the detection of TEM-, SHV-, CTX-M-type beta-lactamase genes, and plasmid-mediated AmpC beta-lactamases (p-AmpC) were performed as previously described \[[@pone.0202276.ref011], [@pone.0202276.ref012]\]. Isolates displaying non-susceptibility to imipenem or meropenem (minimum inhibitory concentration \> 1 μg/mL) were analyzed to determine the presence of carbapenemases, using primers as previously described \[[@pone.0202276.ref006]\].

Clinical analysis {#sec009}
-----------------

Bacteremia was categorized as nosocomial, healthcare-associated, or community acquired, in accordance with the criteria set out by Friedman et al Nursing home-associated infections comprised those occurring in patients residing in nursing homes or who attended day care within 30 days of the onset of bacteremia \[[@pone.0202276.ref013]\]. The Charlson comorbidity index was used to categorize comorbid conditions, identified by reviewing the patients' medical charts \[[@pone.0202276.ref014]\]. Other clinical information included age; sex; date of onset of nosocomial infection; whether antibiotic agents, general anesthesia, chemotherapy, radiation therapy, or immunosuppressive agents such as glucocorticoids were administered within 30 days of the date of onset of bacteremia; intensive care unit admission at the time of bacteremia; source of infection (urinary tract, intra-abdominal, catheter-associated, soft-tissue, pneumonia, or unknown); presence of indwelling devices (peripheral or central venous catheters, urinary catheter, drainage tube(s), nasogastric tube, tracheotomy tube, and devices related to oxygen inhalation, mechanical ventilation, or continuous hemodiafiltration). Inappropriate antimicrobial treatment was defined as the use of an antimicrobial agent to which the pathogen being treated is resistant.

Statistical analysis {#sec010}
--------------------

The statistical analysis was performed using Stata software version 13 (Stata Corporation College Station, TX, USA). For the univariate statistical analysis of dichotomous outcomes, Fisher's exact test and logistic regression analysis were used to compare categorical and continuous explanatory variables, respectively. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to determine the strength of any associations that emerged. P values \< .05 were considered statistically significant, and all probabilities were two-tailed. In the risk factor analysis for ESBL-EC bacteremia, multivariate logistic regression analysis was performed with nosocomial infection, nursing home-associated infection, and used antibiotic(s) within 30 days. It was thought that nosocomial and nursing home-associated infection might be associated with ESBL-producing organism acquisition while the last factor (used antibiotic(s) within 30 days) may be associated with ESBL-producing organisms' selection. These factors have been shown to be clinically significant variables of ESBL-producing organisms in previous studies \[[@pone.0202276.ref015]--[@pone.0202276.ref017]\]. The number of variables included in the multivariate analysis was restricted to 10% of the number of ESBL-producing isolates \[[@pone.0202276.ref018]\]. In the risk factor analysis for 14-day mortality, a multivariate analysis could not be performed because there were only ten deaths.

Results {#sec011}
=======

Microbiology results {#sec012}
--------------------

During the study period, there were 115 unique cases of bacteremia caused by *E*. *coli*: 30 (26.1%) were due to ESBL-EC and 85 (73.9%) were due to non-ESBL-EC. The antibiotic susceptibility patterns of all isolates are shown in [Table 1](#pone.0202276.t001){ref-type="table"}. Among the cases, a high proportion was resistant to piperacillin-tazobactam, cefmetazole, gentamicin, tobramycin, levofloxacin, ciprofloxacin, and trimethoprim-sulfamethoxazole. Notably, 83.3% of cases were resistant to ciprofloxacin and 50% were resistant to trimethoprim-sulfamethoxazole, compared with 15.3% and 17.6% of controls, respectively.

10.1371/journal.pone.0202276.t001

###### Antimicrobial resistance of ESBL-EC and non-ESBL-EC isolates.

![](pone.0202276.t001){#pone.0202276.t001g}

  Antimicrobial agent                               ESBL-EC (n = 30)   Non-ESBL-EC (n = 85)   *P* value
  ------------------------------------------------- ------------------ ---------------------- -----------
  Piperacillin-tazobactam                           5 (16.7)           1 (1.2)                .005
  Cefmetazole                                       5 (16.7)           2 (2.4)                .01
  Flomoxef                                          1 (3.3)            1 (1.2)                .46
  Imipenem                                          1 (3.3)            0                      .26
  Meropenem                                         1 (3.3)            0                      .26
  Gentamicin                                        12 (40)            5 (5.9)                \< .001
  Tobramycin                                        12 (40)            5 (5.9)                \< .001
  Amikacin                                          1 (3.3)            0                      .26
  Levofloxacin                                      24 (80)            14 (16.5)              \< .001
  Ciprofloxacin                                     25 (83.3)          13 (15.3)              \< .001
  Fosfomycin[\*](#t001fn002){ref-type="table-fn"}   0                  3 (3.5)                .57
  Trimethoprim-sulfamethoxazole                     15 (50)            15 (17.6)              \< .001

Data are presented as n (%). ESBL-EC, extended-spectrum beta-lactamase-producing *E*. *coli*; non-ESBL-EC, non-extended-spectrum beta-lactamase-producing *E*. *coli*.

\* Clinical Laboratory Standards Institute breakpoint is available for urine isolates only.

The ST and distribution of antimicrobial resistance genes of the ESBL-EC isolates are shown in [Table 2](#pone.0202276.t002){ref-type="table"}. CTX-M-27 was most prevalent, followed by CTX-M-14. Three isolates possessed both CTX-M (two CTX-M-2 and one CTX-M-27) and IMP-6 genes. ST131 was the most prevalent ST (19/30, 63.3%). CTX-M-27 (8/19, 42.1%) and CTX-M-14 (5/19, 26.3%) were the most common ESBL-associated genes. Two of the three CTX-M+IMP-6 isolates were ST131.

10.1371/journal.pone.0202276.t002

###### Distribution of ESBL-EC antimicrobial resistance genes and sequence types.

![](pone.0202276.t002){#pone.0202276.t002g}

  Genotype (n = 30 cases)                             Number (%) of isolates   MLST (number of isolates)
  --------------------------------------------------- ------------------------ -----------------------------------
  CTX-M-27                                            10 (33.3)                ST131 (8), ST2179 (1), ST2750 (1)
  CTX-M-14                                            7 (23.3)                 ST131 (5), ST62 (1), ST405 (1)
  CTX-M-2 &IMP-6                                      2 (6.7)                  ST131 (1), ST2750 (1)
  CTX-M-2                                             2 (6.7)                  ST131 (2)
  CTX-M-14 & CMY-2                                    2 (6.7)                  ST95 (1), ST648 (1)
  SHV-12                                              1 (3.3)                  ST362 (1)
  Novel CTX-M[^a^](#t002fn002){ref-type="table-fn"}   1 (3.3)                  ST648 (1)
  CTX-M-61                                            1 (3.3)                  ST131 (1)
  CTX-M-27 & IPM-6                                    1 (3.3)                  ST131 (1)
  CTX-M-19                                            1 (3.3)                  ST131 (1)
  CTX-M-15                                            2 (3.3)                  ST847 (1), ST2179 (1)

MLST, multi-locus sequence typing; ESBL-EC, extended-spectrum beta-lactamase producing *E*. *coli*.

^a^ GenBank accession number: KY964289

Clinical results {#sec013}
----------------

The patients' demographic characteristics and risk factors for ESBL-EC bacteremia are listed in [Table 3](#pone.0202276.t003){ref-type="table"}. The following variables were identified as risk factors for ESBL-EC bacteremia in the univariable analysis: younger age; community-onset, nosocomial, and nursing home-associated infections; administration of antibiotic, general anesthetic, or immunosuppressive agents within 30 days of bacteremia onset; connective tissue disease, paraplegia or hemiplegia, dementia, and leukemia; a higher Charlson comorbidity index; and urinary or central venous catheterization. In the multivariate analysis, nursing home-associated infection (OR, 7.98; 95% CI, 1.56--40.9) and antibiotic administration within the preceding 30 days (OR, 5.11; 95% CI, 1.61--16.2) were independent risk factors for ESBL-EC bacteremia; however nosocomial infection (OR, 1.28; 95% CI, 0.4--4.17) was not. We quantified the severity of multicollinearity among the predictor variables in the regression analysis by calculating the variance inflation factor (VIF). The VIF values were 1.48, 1.05, and 1.44 for nosocomial and nursing home-associated infections, and used antibiotics within 30 days, respectively. The fact that these variables were sufficiently smaller than 5.0 means that each predictor variable was uncorrelated with the other predictors and the multicollinearity among them was vanishingly small.

10.1371/journal.pone.0202276.t003

###### Univariate and multivariate analysis of risk factors associated with ESBL-EC compared with non-ESBL-EC isolates in bacteremic patients.

![](pone.0202276.t003){#pone.0202276.t003g}

  Variable                                              ESBL-EC       Non-ESBL-EC   Univariate analysis    Multivariate analysis                       
  ----------------------------------------------------- ------------- ------------- ---------------------- ----------------------- ------------------- ------
  Age, mean (SD), y                                     66.5 (17.2)   72.3 (10.8)   0.97 (0.94--1.00)      .04                                         
  Sex: male                                             19            37            2.22 (0.88--5.87)      .09                                         
  Healthcare-associated infection                       9             31            0.75 (0.27--1.97)      .66                                         
  Nosocomial infection                                  21            40            2.63 (1.00--7.25)      .04                     1.28 (0.40--4.17)   .678
  Nursing home-associated infection                     6             3             6.69 (1.31--44.50)     .009                    7.98 (1.56--40.9)   .013
  Days to onset of nosocomial infection, median (IQR)   24 (15--79)   28 (12--50)   1.00 (0.99--1.01)      .63                                         
  Used antibiotic(s) within 30 days                     22            28            5.51 (2.05--16.22)     \< .001                 5.11 (1.61--16.2)   .006
  General anesthesia within 30 days                     7             6             3.94 (1.02--15.8)      .04                                         
  Chemotherapy within 30 days                           2             11            0.48 (0.05--2.43)      .51                                         
  Radiation within 30 days                              1             3             0.94 (0.02--12.29)     \>.99                                       
  Immunosuppressants within 30 days                     14            21            2.64 (1.01--6.93)      .04                                         
  Intensive care unit admission before infection        8             10            2.70 (0.82--8.70)      .08                                         
  Source of infection:                                                                                                                                 
   Urinary tract                                        13            49            0.56 (0.22--1.41)      .20                                         
   Intra-abdominal                                      10            22            1.43 (0.51--3.81)      .48                                         
   Catheter-associated                                  2             2             2.93 (0.20--42.2)      .28                                         
   Soft-tissue                                          1             1             2.86 (0.04--229.6)     .46                                         
   Pneumonia                                            0             4             0 (0--4.32)            .57                                         
   Unknown                                              4             7             1.71 (0.34--7.37)      .47                                         
  Comorbid condition(s):                                                                                                                               
   Malignancy                                           11            38            0.72 (0.27--1.82)      .52                                         
   Diabetes mellitus                                    8             19            1.26 (0.42--3.56)      .63                                         
   Connective tissue disease                            7             3             8.12 (1.69--52.53)     .003                                        
   Cerebral vascular disease                            5             9             1.68 (0.40--6.23)      .52                                         
   Peripheral vascular disease                          3             4             2.23 (0.31--14.12)     .37                                         
   Paraplegia or hemiplegia                             6             2             10.11 (1.67--108.70)   .004                                        
   Dementia                                             6             1             20.3 (2.30--971.50)    .001                                        
   Cardiovascular disease                               5             15            0.93 (0.24--3.08)      \>.99                                       
   Chronic liver disease                                4             13            0.85 (0.19--3.10)      \>.99                                       
   Renal insufficiency                                  4             13            0.85 (0.19--3.10)      \>.99                                       
   Chronic pulmonary disease                            5             8             1.91 (0.45--7.37)      .32                                         
   Leukemia                                             4             0             Inf (1.99--Inf)        .004                                        
   Lymphoma                                             2             2             2.93 (0.20--42.19)     .28                                         
   Peptic ulcer                                         2             0             Inf (0.54--Inf)        .07                                         
  Charlson comorbidity index, mean (SD)                 4.2 (2.2)     2.7 (2.1)     1.34 (1.11--1.62)      .003                                        
  Charlson comorbidity index \>2                        21            33            3.63 (1.39--10.18)     .005                                        
  Indwelling devices:                                                                                                                                  
   Peripheral catheterization                           10            17            1.99 (0.70--5.50)      .21                                         
   Urinary catheterization                              10            11            3.32 (1.10--10.07)     .03                                         
   Oxygen inhalation                                    7             11            2.05 (0.60--6.56)      .24                                         
   Central venous catheter                              7             4             6.04 (1.39--30.70)     .007                                        
   Drainage tube                                        2             6             0.94 (0.09--5.66)      \>.99                                       
   Tracheotomy tube                                     2             2             2.93 (0.20--42.19)     .28                                         
   Nasogastric tube                                     2             2             2.93 (0.20--42.19)     .28                                         
   Mechanical ventilation                               2             2             2.963(0.20--42.19)     .28                                         
   Continuous hemodiafiltration                         1             1             2.86 (0.04--229.6)     .46                                         

ESBL-EC, extended-spectrum beta-lactamase-producing *E*. *coli*; non-ESBL-EC, non-extended-spectrum beta-lactamase-producing *E*. *coli*; OR, odds ratio; CI, confidential interval; IQR, interquartile range; SD, standard deviation; CCI, Charlson comorbidity index; Inf, infinity.

Overall, 14 day-mortality was 8.7% (10/115) with 4.7% (4/85) for non-ESBL-EC, 14.8% (4/27) for ESBL-only-EC, 20% (6/30) for ESBL-EC, and 66.7% (2/3) for ESBL/IMP-6-EC. [Table 4](#pone.0202276.t004){ref-type="table"} shows the results of the univariate analysis of 14-day mortality. Multiple factors, such as the use of inadequate antibiotic therapy within 24 hours; prior use of any antibiotic and specifically of any carbapenem; infection arising from the urinary tract, soft-tissue, or an unknown source; chronic liver disease; central venous catheterization; presence of a nasogastric tube; mechanical ventilation; ESBL-EC and ESBL/IMP-6-EC were also significantly associated with 14-day mortality.

10.1371/journal.pone.0202276.t004

###### Univariate analysis of risk factors for all-cause mortality within 14 days after onset of bacteremia due to *E*. *coli*.

![](pone.0202276.t004){#pone.0202276.t004g}

  Variables                                   Survived (n = 105)   Died (n = 10)   OR        95% CI         *P* value
  ------------------------------------------- -------------------- --------------- --------- -------------- -----------
  Sex: male                                   50                   6               1.53      0.43--5.41     .51
  Intensive care unit after infection         17                   4               2.91      0.82--10.33    .08
  Inadequate antibiotic therapy within 24 h   9                    5               9.11      2.63--31.55    \< .001
  Community-onset infection                   51                   3               0.55      0.14--2.15     .38
  Healthcare-associated infection             38                   2               0.53      0.11--2.48     .41
  Nosocomial infection                        54                   7               1.80      0.47--6.99     .38
  Nursing home-associated infection           7                    2               2.80      0.59--13.19    .17
  Antibiotic(s) used within 30 days:                                                                        
   Any antibiotic                             41                   9               10.93     1.38--86.3     .004
   Any carbapenem                             11                   5               6.18      1.79--21.4     \< .001
   Any quinolone                              7                    1               1.52      0.19--12.0     .69
  Immunosuppressant used within 30 days       30                   5               2.18      0.63--7.52     .21
  General anesthesia within 30 days           12                   1               0.79      0.10--6.22     .82
  Chemotherapy within 30 days                 11                   2               1.84      0.39--8.68     .43
  Radiation within 30 days                    4                    0               \<0.001   0--Inf         .52
  Intensive care unit admission               16                   2               1.21      0.26--5.68     .81
  Source of infection:                                                                                      
   Urinary tract                              60                   2               0.21      0.046--1.01    .03
   Intra-abdominal                            28                   4               1.71      0.48--6.05     .40
   Catheter-associated                        4                    0               \<0.001   0--Inf         .52
   Soft-tissue                                1                    1               8.21      1.03--65.3     .02
   Pneumonia                                  4                    0               \<0.001   0--Inf         .52
   Unknown                                    8                    3               4.39      1.13--17.0     .02
  Comorbid condition(s):                                                                                    
   Malignancy                                 45                   4               0.86      0.24--3.04     .81
   Diabetes mellitus                          25                   2               0.83      0.18--3.9      .81
   Connective tissue disease                  9                    1               1.07      0.14--8.45     .95
   Cerebrovascular disease                    12                   2               1.95      0.41--9.19     .39
   Peripheral vascular disease                7                    0               \<0.001   0--Inf         .39
   Paraplegia or hemiplegia                   7                    1               1.20      0.43--3.36     .73
   Dementia                                   7                    0               \<0.001   0--Inf         .39
   Cardiovascular disease                     19                   1               0.54      0.068--4.26    .55
   Chronic liver disease                      12                   5               6.26      1.81--21.7     \< .001
   Renal insufficiency                        15                   2               1.46      0.31--6.86     .63
   Chronic pulmonary disease                  11                   2               2.10      0.45--9.89     .34
   Leukemia                                   3                    1               3.55      0.45--28.0     .20
   Lymphoma                                   4                    0               \<0.001   0--Inf         .52
   Peptic ulcer                               2                    0               \<0.001   0--Inf         .65
  Indwelling device:                                                                                        
   Peripheral catheter                        25                   2               0.74      0.16--3.50     .70
   Urinary catheter                           17                   4               2.78      0.78--9.85     .10
   Oxygen inhalation                          15                   3               2.15      0.56--8.31     .25
   Central venous catheter                    8                    3               4.18      1.08--16.18    .02
   Drainage tube                              6                    2               3.16      0.67--14.87    .12
   Tracheotomy tube                           2                    2               6.50      1.38--30.61    .006
   Nasogastric tube                           1                    3               13.17     3.39--51.14    \< .001
   Mechanical ventilation                     2                    2               6.50      1.38--30.61    \< .001
   Continuous hemodiafiltration               1                    1               5.54      0.70--43.7     .07
  Empiric treatment with a carbapenem         43                   6               1.89      0.53--6.70     .31
  Carbapenem use after susceptibility test    66                   4               0.36      0.10--1.27     .09
  Carbapenem use                              68                   6               0.71      0.20--2.51     .59
  Age ≥ 65 years                              85                   6               0.36      0.10--1.28     .10
  Charlson comorbidity score of \> 2          47                   7               2.62      0.68--10.12    .15
  Age, mean years (SD)                        71.4 (12.1)          64.1 (19.5)     0.97      0.93--1.01     .10
  Charlson comorbidity index, mean (SD)       4.3 (3.1)            3.0 (2.1)       1.26      0.97--1.62     .08
  ESBL-only-EC                                23                   4               2.36      0.45--10.94    .24
  ESBL-EC                                     24                   6               4.97      1.08--26.01    .02
  ESBL/IMP-6-EC                               1                    2               24.17     1.15--1527.7   .02

OR, odds ratio; CI, confidential interval; SD, standard deviation; ESBL-only-EC, extended-spectrum beta-lactamase-producing only *E*. *coli*; ESBL-EC, extended-spectrum beta-lactamase-producing *E*. *coli*; non-ESBL-EC, non-extended-spectrum beta-lactamase-producing *E*. *coli*

Discussion {#sec014}
==========

Worldwide, the prevalence of ESBL-EC has varied widely and is increasing. Matsumura et al. found that 13.9% of 706 cases of *E*. *coli* bacteremia occurring from 2005--2012 were due to ESBL-producing strains, while Namikawa et al. recently reported that 24.0% of 129 cases of *E*. *coli* bacteremia from 2011--2015 were due to ESBL-EC \[[@pone.0202276.ref003], [@pone.0202276.ref019]\]. In our study, a total of 115 unique cases of *E*. *coli* bacteremia were identified and, of these, 30 (26.1%) were caused by ESBL-EC. The proportion of carbapenemase-producing *E*. *coli* was 2.6%, and all cases produced IMP-6. The prevalence of carbapenemase-producing *E*. *coli* among all cases of *E*. *coli* bacteremia in Japan has not previously been reported. In a recent analysis of 4875 Enterobacteriaceae isolates collected in Japan between 2010 and 2013, Ohno et al. reported that the prevalence of IMP-6-producing strains ranged from 0.08% to 0.92%, depending on the species and biologic specimen from which the isolates were cultured \[[@pone.0202276.ref020]\]. Because IMP-6-producing isolates typically exhibit low-level resistance to the carbapenems, they are often overlooked; however, it is important that these strains be continuously monitored using highly sensitive tests \[[@pone.0202276.ref006]\].

Multilocus sequence typing revealed that 19 of the 30 ESBL-EC isolates (63.3%) were ST131. The global increase in ESBL-EC is associated with a pandemic clonal group known as ST131 that includes CTX-M-type-producing ESBLs \[[@pone.0202276.ref006]\]. It is known that ST131 *E*. *coli* sequentially acquires antimicrobial resistance genes and develops resistance to multiple classes of antibiotics, including aminoglycosides, fluoroquinolones, and sulfamethoxazole-trimethoprim \[[@pone.0202276.ref002]\]. This could explain the high rates of multi-class antibiotic resistance among the ESBL-EC isolates in our study. Matsumura et al. recently reported an increase in CTX-M-27-producing ST131 isolates in Japan, named C1-M27 \[[@pone.0202276.ref004]\]. A third of our ESBL isolates produced CTX-M-27, and 80% of these were ST131. The second most prevalent CTX-M was CTX-M-14, 71% of which were ST131. Of 115 isolates, three (2.6%) produced both IMP-6 and either CTX-M-2 or CTX-M-27; and two were ST131. *E*. *coli* strains producing both IMP-6 and CTX-M-2 have been reported, although this is the first study to report an *E*. *coli* isolate producing both IMP-6 and CTX-M-27 \[[@pone.0202276.ref021]\]. This finding alerts us to the future risk that C1-M27 might acquire higher-level antimicrobial resistance genes, such as carbapenemase-resistance genes.

As reported, many factors are associated with infection or colonization by ESBL-EC \[[@pone.0202276.ref006], [@pone.0202276.ref007], [@pone.0202276.ref009], [@pone.0202276.ref010], [@pone.0202276.ref019], [@pone.0202276.ref020], [@pone.0202276.ref022]--[@pone.0202276.ref024]\]. By comparing ESBL-EC bacteremia and non ESBL-EC bacteremia, we identified risk factors of ESBL-EC in patients with EC bacteremia. At univariate analysis, multiple factors were found to be associated with ESBL-EC; however, at multivariate analysis, we chose three representative risk factors due to sample size constraints. These three factors were traditionally regarded as being important for the isolation of multidrug resistant organisms \[[@pone.0202276.ref015]--[@pone.0202276.ref017]\]. Historically, multidrug resistant organisms are isolated from severely ill, hospitalized patients in intensive care \[[@pone.0202276.ref023]\]. However, community acquired ESBL-EC infection is reported to be as important as nosocomial ESBL-EC infection \[[@pone.0202276.ref025]\]. From this perspective, it is interesting that nosocomial infection was not a significant risk factor for ESBL-EC bacteremia at multivariate analysis. On the other hand, it has been reported that residents in nursing homes have high risk of carriage of ESBL-EC \[[@pone.0202276.ref024], [@pone.0202276.ref026]\]. Our result is consistent with these reports in that nursing home-associated infection was significantly associated with ESBL-EC bacteremia. Finally, exposure to antibiotics has been reported as the most significant risk factor in many studies \[[@pone.0202276.ref001], [@pone.0202276.ref005], [@pone.0202276.ref009], [@pone.0202276.ref015]--[@pone.0202276.ref017], [@pone.0202276.ref019], [@pone.0202276.ref024], [@pone.0202276.ref026]\]. Antibiotic exposure is associated with multidrug resistant organisms, not only by inducing mutations associated with antibiotic resistance, but also by selecting resistant organisms; which is called selection pressure. In our study, antibiotic exposure within 30 days was a significant risk factor for ESBL-EC bacteremia.

A number of studies found no significant association between ESBL production and crude mortality \[[@pone.0202276.ref015]--[@pone.0202276.ref017], [@pone.0202276.ref019]\]. Conversely, several other studies observed that patients with infection due to antibiotic-resistant organisms tended to have poorer outcomes \[[@pone.0202276.ref022], [@pone.0202276.ref027]\]. Inappropriate empiric treatment, frequently observed in antibiotic-resistant *E*. *coli* infection, is the main determinant of mortality. Again, due to sample size constraints, we performed only univariate analysis, revealing multiple significant risk factors of death. Patients with ESBL-EC bacteremia and ESBL/IMP-6-EC bacteremia may have poorer prognosis; however, there is need for further study to appropriately identify the risk factors of death.

There are some limitations to our study. First, it involved a single center; hence, the generalizability of our results to other settings may not be feasible. Second, the limited number of patients prevented us from performing a more detailed statistical analysis. The difference in mortality among non-ESBL-EC, ESBL-EC, and ESBL/IMP-6-EC cannot be attributed to the presence of resistance. For the aim to identify clinically relevant risk factors of resistance and mortality, a multicenter study with a larger study population is warranted.

In conclusion, of 115 unique bloodstream infections caused by *E*. *coli*, 30 (26.1%) were caused by ESBL-EC and three (2.6%) by carbapenemase-producing *E*. *coli*. All carbapenemase-producing *E*. *coli* were IMP-6-producing strains that also produced ESBLs. Among the ESBL-EC, 33.3% possessed CTX-M-27 and 30% harbored CTX-M-14. Nineteen (63.3%) were ST131. Nursing home-associated infections and administration of antibiotic agents within the previous 30 days were associated with ESBL-EC bacteremia. Overall, 14 day-mortality was 8.7% (10/115) with 4.7% (4/85) for non-ESBL-EC, 14.8% (4/27) for ESBL-only-EC, 20% (6/30) for ESBL-EC, and 66.7% (2/3) for ESBL/IMP-6-EC; however, the sample size in this study was not sufficient to evaluate the clinical impact on mortality, and further studies with larger sample sizes are warranted.
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